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Abstract
Background: The pulmonary artery catheter (PAC) remains widely used in acute lung injury (ALI) despite known
complications and little evidence of improved short-term mortality. Concurrent with NHLBI ARDS Clinical Trials Network
Fluid and Catheters Treatment Trial (FACTT), we conducted a prospectively-defined comparison of healthcare costs and
long-term outcomes for care with a PAC vs. central venous catheter (CVC). We explored if use of the PAC in ALI is justified by
a beneficial cost-effectiveness profile.
Methods: We obtained detailed bills for the initial hospitalization. We interviewed survivors using the Health Utilities Index
Mark 2 questionnaire at 2, 6, 9 and 12 m to determine quality of life (QOL) and post-discharge resource use. Outcomes
beyond 12 m were estimated from federal databases. Incremental costs and outcomes were generated using MonteCarlo
simulation.
Results: Of 1001 subjects enrolled in FACTT, 774 (86%) were eligible for long-term follow-up and 655 (85%) consented.
Hospital costs were similar for the PAC and CVC groups ($96.8k vs. $89.2k, p = 0.38). Post-discharge to 12 m costs were
higher for PAC subjects ($61.1k vs. 45.4k, p = 0.03). One-year mortality and QOL among survivors were similar in PAC and
CVC groups (mortality: 35.6% vs. 31.9%, p = 0.33; QOL [scale: 0–1]: 0.61 vs. 0.66, p = 0.49). MonteCarlo simulation showed
PAC use had a 75.2% probability of being more expensive and less effective (mean cost increase of $14.4k and mean loss of
0.3 quality-adjusted life years (QALYs)) and a 94.2% probability of being higher than the $100k/QALY willingness-to-pay
threshold.
Conclusion: PAC use increased costs with no patient benefit and thus appears unjustified for routine use in ALI.
Trial Registration: www.clinicaltrials.gov NCT00234767
Citation: Clermont G, Kong L, Weissfeld LA, Lave JR, Rubenfeld GD, et al. (2011) The Effect of Pulmonary Artery Catheter Use on Costs and Long-Term Outcomes
of Acute Lung Injury. PLoS ONE 6(7): e22512. doi:10.1371/journal.pone.0022512
Editor: German Malaga, Universidad Peruana Cayetano Heredia, Peru
Received March 14, 2011; Accepted June 27, 2011; Published July 21, 2011
Copyright:  2011 Clermont et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was entirely funded from NIH R01-HS-11620 & N01-HR-46064. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: clermontg@upmc.edu
Introduction
The National Heart, Lung and Blood Institute (NHLBI) Acute
Respiratory Distress Syndrome (ARDS) Network recently reported
the results of the Fluid and Catheter Treatment Trial (FACTT), a
multicenter study that simultaneously randomized subjects with
acute lung injury (ALI) to one of two fluid management strategies
(liberal or conservative fluid administration) guided by one of two
hemodynamic monitoring devices (a pulmonary artery catheter
(PAC) or a central venous catheter (CVC)). FACTT failed to
demonstrate that PAC-guided fluid management of patients with
ALI improved hospital outcome.[1] Other studies have also been
unable to show improved outcomes through use of the PAC and
some have attributed harm to its use.[2–4]
Nonetheless, recent evidence suggests several hundred thousand
Americans receive PAC-guided care each year for ALI and other
conditions.[5] An argument in favor of continued PAC use is that the
increased physiologic data available to clinicians facilitates clinical
decision-making, which may reduce time in the intensive care unit
(ICU), time requiring mechanical ventilation, and the considerable
hospital and post-discharge morbidity and healthcare costs of
ALI.[6–9] Therefore, despite lack of evidence in improving short-
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term outcomes in critically ill patients with ALI, the PAC could be
associated with decreased short and long-term resource use.
Materials and Methods
Objective
We hypothesized that the PAC could have long-term economic
impacts not previously evaluated in a recently published
multicenter short-term efficacy trial. Concurrent with the FACTT
trial, we conducted a prospective economic assessment of the PAC
(EA-PAC study) out to one year after hospital discharge to
determine the clinical and economic consequences of using the
PAC in the management of ALI.[10]
Study design and participants
Details of the study design for the underlying ‘parent’ trial,
FACTT, were published previously.[1] Briefly, FACTT was a
262 factorial design multicenter trial conducted by the NHLBI
ARDS Network (ClinicalTrials.gov number NCT00281268)
evaluating two types of catheters (PAC vs. CVC) and two fluid
strategies (liberal vs. conservative) in the management of patients
with ALI, with a total enrolment of 1001 patients. A liberal fluid
strategy aimed at a central venous pressure (CVP) of 10–14 mmhg
(by CVC) or pulmonary artery occlusion pressure (PAOC) of 14–
18 mmHg (by PAC), while a conservative strategy aimed at a
CVP,4 and PAOP,8 mmHg in the CVC and PAC arms. The
trial’s primary end-point was 60-day all-cause mortality.
Table 1. Cost weight in the assessment of post-discharge resource use.
Cost weight Justification
Home oxygen First day = 600$ +6.50/day other days www.vgmdclink.com/pdffiles/MorrisonOxygenCostStudyJune2006.
pdf
Home Help $100/day 1999 CMS cost report, indexed to 2009
Rehab $800/day 1999 CMS cost report, indexed to 2009
Skilled nursing facility (vent) $1500/day 1999 CMS cost report, indexed to 2009
ED visits $800/day 1999 CMS cost report, indexed to 2009
DR visits $200/day 1999 CMS cost report, indexed to 2009
Rehospitalization Total days*1500+ICU day*(2600–1500)+vent
days*(2800–2600)
Cost of individual days obtained from State discharge database
analysis9
Medications $10/day Estimated
Lost days of work $200/day Median US daily income
CMS - Center for Medicare and Medicaid Services.
doi:10.1371/journal.pone.0022512.t001
Figure 1. Quorum chart of the EA-PAC cohort.
doi:10.1371/journal.pone.0022512.g001
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To participate in the EA-PAC study, subjects had to be enrolled
in FACTT and they or their proxies had to provide informed
consent for the follow-up procedures. EA-PAC was approved by
the NHLBI ARDS Network steering committee and the
institutional review boards (IRBs) of all participating sites.
Coordinating center approval for the long-term follow-up study
was obtained from the University of Pittsburgh IRB. FACTT was
monitored by a data safety and monitoring board and the long-
term follow-up was additionally monitored by an NHLBI-funded
advisory board.
Long-Term Outcomes
For those consenting to long-term follow-up, we conducted
interviews blinded to treatment assignment at 2, 6, 9 and 12
months. We administered the Health Utilities Index Mark 2 (HUI-
2) questionnaire to assess health utility.[11] Where possible, we
spoke with the subject.[12] One-year vital status and date of post-
discharge death when applicable were ascertained from hospital
records, interview, and search of the National Death Index.
Costs and resource use
We obtained the detailed hospital bill for the initial hospital-
ization and calculated costs using the Medicare year-specific
hospital and department-specific cost-to-charge ratio (www.cms.
hhs.gov/CostReports). We assessed post-discharge healthcare
costs by collecting information during follow-up interviews on
re-hospitalizations, physician and emergency department visits,
medications, and ancillary support. The cost for post-discharge use
was calculated by multiplying unit cost weights with units of
resource use, where cost weights were estimated from existing data
(Table 1). All costs were then updated and expressed in 2010 US
dollars using the U.S. Census consumer price index.
Table 2. Comparison of EA-PAC and FACTT Cohort.
EA-PAC Cohort
FACTT Cohort not
in EA-PAC Total FACTT cohort p-value
N 655 346 1001
Age, mean (SD) 50.1 (16.0) 49.1 (16.7) 49.8 (16.0) .34
Sex, female, n (%) 308 (47%) 158 (49%) 466 (47%) .74
Race, n (%) ,.001
White non-Hispanic 445 (68%) 196 (57%) 641 (64%)
Black non-Hispanic 136 (21%) 81 (23%) 217 (22%)
Other 74 (11%) 68 (20%) 142 (14%)
Primary Lung injury, n (%) .12
Pneumonia 299 (46%) 172 (50%) 471 (47%)
Sepsis 145 (22%) 88 (26%) 233 (24%)
Aspiration 103 (16%) 46 (13%) 149 (15%)
Trauma 50 (8%) 24 (7%) 74 (7%)
Multiple transfusions 6 (1%) 3 (1%) 9 (1%)
Other 46 (7%) 11 (3%) 57 (6%) .
Co-existing Conditions, n (%)
None 444 (68%) 216 (63%) 660 (66%) .11
Diabetes 110 (17%) 63 (19%) 173 (18%) .66
HIV Infection or AIDS 36 (6%) 35 (10%) 71 (7%) .01
Cirrhosis 24 (4%) 9 (3%) 33 (3%) .46
Solid Tumors 12 (2%) 3 (1%) 15 (2%) .28
Leukemia 12 (2%) 10 (3%) 22 (2%) .37
Lymphoma 6 (1%) 7 (2%) 13 (1%) .16
Immunosuppression 51 (8%) 27 (8%) 78 (8%) 1.0
Apache III score, mean (SD) 93 (31) 95 (30) 94 (31) .51
Medical ICU (%) 421 (64%) 242 (70%) 663 (66%) .07
Cardiorespiratory variables, mean (SD)
MAP (mm Hg) 77 (14) 77 (14) 77 (14) .61
CI (liters/min/m2) 4.1 (1.4) 4.4 (1.5) 4.2 (1.4) .04
Vasopressor use, n (%) 248 (39%) 150 (44%) 398 (40%) .10
Pre-randomization fluid balance (mL) 2875 (3590) 2553 (3417) 2764 (3533) .18
PaO2/FiO2 127 (57) 127 (62) 127 (58) .86
Tidal volume (mL), mean (SD) 452 (99) 490(122) 466 (109) ,.0001
TV (mL/kg of PBW), mean (SD) 6.3 (2.7) 6.8 (3.1) 6.5 (2.9) ,.0001
SD - standard deviation; MAP - Mean arterial pressure; CI - Cardiac index; TV - Tidal volume.
doi:10.1371/journal.pone.0022512.t002
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Data analysis
Non-parametric tests were used to compare continuous data
between treatment of the PAC and CVC arms. Categorical data
and proportions were compared by chi-square. Survival was
evaluated by Kaplan-Meier analysis and groups compared by log-
rank test. W conducted a longitudinal analysis for the repeatedly
measured utilities using the Generalized Estimating Equations
(GEE) method. Linear and quadratic trends over time were
examined in the linear regression models. All analyses were
conducted using SAS 9.0 software (SAS Institute, Cary NC).
Cost-effectiveness
We used the U.S. Public Health Service Panel on Cost-
effectiveness in Health and Medicine recommendations and the
American Thoracic Society guidelines to conduct the economic
analysis from a societal perspective.[10,13] For each subject
enrolled in EA-PAC, we constructed: i.) a stream of costs to one
year post-enrolment based on calculated hospital costs, post-
discharge direct medical costs, and lost wages ; ii.) a stream of
projected lifetime costs based on projected survival (infra vide); iii.)
effect at one year post-enrolment, defined as duration of survival
multiplied by the area under the utility curve over the first year
using utility data from interval interviews, and; iv.) projected
lifetime accrual of quality-adjusted life-years(QALYs).
We calculated an incremental cost-effectiveness ratio (ICER) at
one year based on data collected to one year. We also generated a
reference case as follows. We estimated life expectancy for each
subject alive at one year post-enrolment based on the year 2006
age-, race/ethnicity-, and sex-specific U.S. life tables. We assigned
an average utility of 0.6 beyond one year based on prior
Table 3. Baseline characteristics by treatment assignment for the EA-PAC cohort.
PAC CVC p-value
N 325 330
Age, mean (SD) 50 (16) 50 (16) 0.91
Sex, female, n (%) 153 (47) 155 (47) 0.98
Race, n (%) 0.04
White non-Hispanic 231 (71) 213 (65)
Black non-Hispanic 63 (19) 73 (22)
Hispanic 22 (7) 40 (12)
Other 9 (3) 4 (1)
Primary lung injury, n (%) 0.62
Pneumonia 153 (47) 146 (44)
Sepsis 70 (22) 75 (23)
Aspiration 46 (14) 57 (17)
Trauma 29 (9) 21 (6)
Multiple transfusions 2 (1) 4 (1)
Other 25 (8) 27 (8)
Co-existing conditions, n (%)
None 217 (67) 227 (69) 0.58
Diabetes 56 (18) 54 (17) 0.85
HIV infection or AIDS 12 (4) 24 (8) 0.04
Cirrhosis 12 (4) 12 (4) 0.99
Solid tumors 5 (2) 7 (2) 0.56
Leukemia 8 (3) 4 (1) 0.25
Lymphoma 3 (1) 3 (1) 0.99
Immunosuppression 29 (9) 22 (7) 0.31
APACHE III score, mean (SD) 96 (31) 92 (31) 0.08
Medical ICU, n (%) 208 (64) 213 (65) 0.85
Cardiorespiratory variables, mean (SD)
Mean arterial pressure, mm/Hg 78 (15) 77 (14) 0.50
Cardiac index, L/min/m2 4 (1.4) N/A N/A
Vasopressor use, n (%) 132 (42) 116 (36) 0.13
Pre-randomization fluid balance, mL 2962 (3730) 2790 (3451) 0.61
PaO2:FiO2 ratio 126 (58) 128 (56) 0.56
Tidal volume index, ml/kg, mean (SD) 7.13 (1.54) 7.19 (1.53) 0.65
Time from diagnosis to protocol initiation, mins, mean (SD) 1523 (912) 1365 (815) 0.04
SD= standard deviation; PAC = pulmonary artery catheter; CVC = central venous catheter.
doi:10.1371/journal.pone.0022512.t003
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studies.[8,14] We assigned costs beyond one year to each subject’s
projected remaining years of life based on the National
Expenditure Medical Survey (www.meps.ahrq.gov) and used a
3% annual discount rate for costs and effects.[15] The ICER
comparing PAC and CVC was obtained as the ratio of the
difference in cost to the difference in effect per enrolled subject and
a Monte Carlo sensitivity analysis (5000 simulated trials) was
conducted to reflect uncertainties in costs and effects. We
calculated the overall ICER, the 95% confidence ellipse around
this estimate, and the probability of the ICER falling below $50k/
QALY and below $100k/QALY.[16] We generated a cost-
effectiveness acceptability curve for the reference case. We
generated model estimates for several a priori defined subgroups:
sex, age, ethnicity, fluid strategy, APACHE III score (, and .90),
tidal volume (# and .6.9 cc/kg), time from diagnosis to initiation
of study protocol (# and .21.5 h), and ARDS etiology. We
Figure 2. Survival by treatment arm. Trends seen in the FACTT trial persist to one year of follow-up. Although patients with CVC have higher
cumulative survival, the difference is not significant (p = 0.33, log-rank).
doi:10.1371/journal.pone.0022512.g002
Figure 3. Utility by treatment arm. Median Health-related quality-of-life, measured by the Health Utilities Index, is uniformly low in the EA-PAC
cohort, although the inter-quartile range is wide and individual values spread the entire 0–1 interval. Utilities are lowest at 90 days and improved by 9
months. Subjects assigned to the PAC were no different than those assigned to the CVC.
doi:10.1371/journal.pone.0022512.g003
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conducted secondary sensitivity analyses to evaluate the impact on
cost-effectiveness of expected survival, utility, estimated yearly cost
of health care beyond the first year, physician reimbursements and
discounting rate.
Results
Patients
There were 10,511 patients screened for enrolment at 20 North
American centers between June 8, 2000, and October 3, 2005. Of
the 1001 subjects analyzed in FACTT, 774 (77%) were enrolled at
sites and during time periods for which IRB approval was granted
for the EA-PAC study. Of these 774 subjects, 655 (85%) agreed to
participate and one-year outcome was available in 593 (Figure 1).
Subjects who participated in EA-PAC were generally similar to
those who did not, but were less likely to have HIV infection or
AIDS, more likely to be non-Hispanic whites, and more likely to
have a lower cardiac index and be receiving smaller tidal volumes
at enrolment (Table 2). There were no differences at baseline in
the EA-PAC cohort between subjects assigned to PAC or CVC
treatment other than a slightly longer time to initiation of protocol
and lower proportion of HIV infection or AIDS in PAC subjects
(Table 3).
Clinical outcomes
Mortality estimates from the Kaplan-Meier analysis increased
from 26.2% and 25.1% at two months in the PAC and CVC
groups to 35.6% and 31.9% at one year. Cumulative survival at
one year was similar in the PAC and CVC arms (p= 0.33)
(Figure 2). Of the 531 EA-PAC subjects discharged alive, we
Table 4. Post-discharge resource use.
PAC (n=210) CVC (n=219) All (n =429) p-value
Home oxygen use
Number of subjects, n (%) 66 (31.4%) 64 (29.2%) 130 (30.3%) .62
Duration days, Mean + SD (median) 90.46109.4 (31.5) 86.86108.7 (30.0) 88.66108.7 (30.0) .94
Rehospitalizations
Number of subjects, n (%) 101 (48.1%) 93 (42.5%) 194 (45.2%) .24
Times of re-hospitalization, Mean 6 SD
(median)
3.164.0 (2.0) 2.562.7 (1.0) 2.863.4 (2.0) .32
LOS of re-hospitalization, Mean 6 SD (median) 20.2628.5 (9.5) 17.7623.0 (8.0) 19.0626.0 (9.0) .71
Post-discharge rehabilitation
Number of subjects, n (%) 72 (34.3%) 64 (29.2%) 136 (31.7%) .26
Duration days, Mean 6 SD (median) 72.9694.3 (23.0) 54.0668.4 (21.5) 64.0683.4 (22.0) .67
Post-discharge ED visits
Number of subjects, n (%) 123 (58.6%) 116 (53.2%) 239 (55.8%) .26
Number of ED visits, Mean 6 SD (median) 4.364.5 (2.0) 3.163.1 (2.0) 3.763.9 (2.0) .06
Post-discharge doctors’ visit
Number of subjects, n (%) 203 (96.7%) 214 (98.2%) 417 (97.4%) .33
Number of Doctor visits, Mean 6 SD (median) 20.3622.0 (13.0) 19.4630.6 (12.0) 19.9626.7 (13.0) .10
Post-discharge medications
Number of subjects, n (%) 185 (88.1%) 201 (91.8%) 386 (90.0%) .20
Number of Medications, Mean 6 SD (median) 18.6615.9 (15.0) 17.7615.9 (13.0) 18.1615.9 (14.0) .44
SD - standard deviation; PAC - pulmonary artery catheter; CVC - central venous catheter; NS - non-significant.
doi:10.1371/journal.pone.0022512.t004
Table 5. Estimates of mean costs and effects from Monte Carlo simulations.
PAC, mean (SD) CVC, mean (SD) Incremental
Costs (thousand $)
Hospital cost* 93.3 (4.8) 84.4 (3.7) 8.9
Post-discharge cost to one yr* 46.7 (4.7) 35.2 (3.6) 11.5
Lifetime cost 191.1 (8.5) 176.7 (7.1) 14.4
Effects
Life expectancy 19.0 (1.0) 20.1 (1.0) 21.0
QALY 4.54 (0.21) 4.83 (0.21) 20.30
SD- standard deviation; PAC – Pulmonary artery catheter; CVC – Central venous catheter; QALY – Quality adjusted life-years.
*With replacement of outliers exceeding the 95th percentile.
doi:10.1371/journal.pone.0022512.t005
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conducted at least one interview with 429 (80.7%) subjects or their
proxies. Fifty subjects had only 1 interview, 47 had 2 interviews, 87
had 3 interviews and 245 completed all 4 interviews. Of 1385
interviews, 344 (25%) were obtained from proxies. Median quality
of life was low throughout follow-up but did improve from two
months (0.47 and 0.51, p = 0.47) to one year (0.61 and 0.66,
p = 0.49) (p = 0.004 for trend over time), with the improvement
plateauing at 9 months (p = 0.04 for quadratic trend). There were
no differences in quality of life either at any time point or overall
between the PAC and CVC arms (Figure 3).
Healthcare costs
Overall, subjects incurred long and expensive hospitalizations.
Hospital costs were available for 633 (97%) of the 655 EA-PAC
subjects and were similar for the PAC (n= 312) and CVC (n= 321)
groups ($96.8686.8k vs. $89.2674.5k, p = 0.38). Length of
hospital stay post-enrolment was also similar (24.4619.2 vs.
23.8619.8 days, p = 0.48) (Table 4). However, for patients
discharged alive costs to one year were higher in those receiving
a PAC ($61.1680.6k vs. 45.4665.7) (p = 0.03). Although differ-
ences in post-discharge costs calculated from resource use (Table 5)
did not reach statistical significance, they tended to be consistently
higher in the PAC arm (Figure 4).
Cost-effectiveness
At one year post-enrolment, average total healthcare costs were
$130.46112.6 vs. $115.4698.8k for the PAC and CVC groups
(p = 0.22), while average accrued quality adjusted days were
120.36110.3 vs. 127.56109.7 days (p = 0.50). Estimates of mean
hospital costs (93.364.8 vs. 84.463.7), post-discharge costs to one
year (46.764.7 vs. 35.263.6), lifetime costs after the first year, and
total health care costs (191.168.5 vs. 176.767.1) obtained from
Monte Carlo trials were higher for the PAC cohort (Table 6).
Subjects receiving a PAC had a slightly shorter life-expectancy
(19.061.0 vs. 20.161.0 years) and fewer QALYs (4.5460.21 vs.
4.8360.21 QALYs) than those receiving a CVC (Table 5).
Consequently, the mean of all simulated trials suggested that PAC
use was both more expensive by $14.4 and less effective by 0.30
QALY than CVC use (Table 6). There was a 75.2% probability
that PAC use was both less effective and more expensive, and
97.4% and 94.2% probabilities that PAC use exceeded the $50k/
QALY and $100k/QALY willingness-to-pay thresholds (Figure 5,
panel A). A cost-effectiveness acceptability curve suggests that a
maximum of only 20.8% of simulations could ever be acceptable,
even if unlimited financial resources were available (PAC use
.$1M/QALY) (Figure 5, Panel B).
Sensitivity analyses
The cost-effectiveness estimates were robust to varying assump-
tions regarding costs and effects. Decreasing life expectancy to half
that of an age-, race-, and sex-matched cohort marginally widened
incremental costs to $16.6k (+15%; where a positive value
indicates that the PAC is more costly), while incremental benefit
was also lower at 20.21 QALY (230%; where a negative value
indicates that the PAC is less effective). Increasing or reducing the
projected utilities beyond one year by 25% changed the estimated
decrement with PAC use of 20.30 QALYs per subject to 20.35
(+17%) and 20.24 (220%). Increasing the annual discount rate to
5% widened incremental costs slightly to 15.9 k (+10%), while
narrowing incremental QALYs to 20.19 (237%). Halving to
doubling annual healthcare costs beyond one year resulted in
incremental costs with PAC use of $18.4k (+28%) and $10.8k
Figure 4. Post-discharge resource use. Overall post-discharge costs were significantly higher in patients assigned to the PAC. There was a trend
in most categories of costs favoring CVC, but only post-discharge rehabilitation costs were significantly different. Of note, the difference was most
apparent at the 9 and 12 month follow-up point (data not shown).
doi:10.1371/journal.pone.0022512.g004
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(225%). Halving to doubling physician reimbursements had
minimal impact on incremental costs. No combination of factors
produced a mean PAC ICER better than $50k/QALY.
Subgroup analyses
The probability that PAC use is cost-effective varied by
subgroup. More favorable profiles were seen in patients who were
treated with a conservative fluid strategy (Figure 5, panel C), had
higher APACHE III scores, were ventilated with low tidal
volumes, were younger, were of Hispanic descent, suffered from
pneumonia as the underlying diagnosis, and were treated earlier
(Figure 5, panel D and Table 6). Yet none of the subgroups
examined had .50% of the simulations with ICER ,$50k/
QALY.
Discussion
Consistent with prior series of subjects with ALI, the patients
enrolled in this trial incurred significant post-discharge morbidity
and high costs of care.[6,8,17] Both hospital and post-discharge
costs were higher in PAC subjects, in association with an increased
incidence of rehospitalization and rehabilitative care, although
differences in post-discharge costs did not reach statistical
significance. There was no evidence that management with a
PAC had any salutary benefits on these outcomes. Indeed, subjects
managed with the PAC incurred higher costs and perhaps fared
worse, a finding that extends results of the short-term efficacy trial.
These findings were robust to multiple sensitivity analyses and
were broadly consistent across a variety of subgroups. Thus, with
respect to conventional management with a CVC, the FACTT
trial suggests use of the PAC in ALI is ineffective, more expensive,
and associated with increased long-term morbidity and costs after
hospital discharge.
We tested PAC use in a setting where data from the catheter
drove explicit protocolized instructions for titration of intravenous
fluids, diuretics, and vasoactive agents. Our results were similar
regardless of whether the protocols advocated liberal or conser-
vative fluid management. A potential criticism of our findings is
that they may not be generalizable to the setting where expert
clinicians make individualized decisions based on hemodynamic
data. However, a recent British study randomized critically ill
subjects to monitoring with the PAC where all treatment decisions
Table 6. Mean estimates of costs and effects for EA-PAC subgroups.
N
Incremental
Costs ($k)
Incremental
Effects (QALY)
% trials with
PAC inferior
% trials with PAC
, $50k/QALY
All 593 14.4 20.30 75.2 2.6
Age group
,45 213 10.4 20.11 35.1 24.8
45–64 256 9.4 20.69 68.5 1.9
.64 124 33.5 20.11 53.1 6.1
Sex
Female 288 18.3 20.21 57.8 7.9
Male 305 11.2 20.39 61.1 7.6
Ethnicity
White non-Hispanics 408 0.9 20.44 61.1 6.2
Black non-Hispanics 120 50.5 0.06 44.1 7.8
Hispanics 54 221.7 20.49 15.3 48.3
Fluid strategy
Liberal 300 18.7 20.58 80.1 2.0
Conservative 293 9.7 2.03 34.7 29.0
APACHE III score
.90 288 27.8 0.44 13.9 40.1
#90 285 2.7 20.62 53.8 4.5
Delay to initiation of
protocol (hours)
#21.5 298 28.8 20.40 20.8 29.1
.21.5 300 36.5 20.18 66.2 1.7
Tidal volume (cc/kg)
.6.9 268 11.5 20.61 67.1 2.7
#6.9 254 18.0 0.29 21.4 44.4
Diagnosis
Sepsis 137 18.7 20.40 70.3 4.0
Pneumonia 271 2.1 20.44 38.2 24.6
Aspiration 90 37.9 20.25 55.9 8.3
PAC – Pulmonary artery catheter; QALY – quality-adjusted life-year.
doi:10.1371/journal.pone.0022512.t006
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remained at the discretion of the treating clinician. Despite the
differences in study design, the British study also found that PAC
use yielded no cost savings and potentially worse outcomes.[18]
The authors further concluded that it would be cost-effective to
withdraw PACs from all British ICUs.
One and two-year follow-ups of patients with ALI suggest that
burden of chronic illness, rather than any acute care sequence of
event, is the key determinant of long-term morbidity.[6,7] The
increase in resource use and post-discharge costs observed in
patients treated with the PAC does not contradict such
observations. These observations would suggest that the PAC
alters the course of an existing chronic illness or gives rise to an
additional burden unaccounted for by what is traditionally
perceived as a chronic illness. For example, it known that
increased inflammation is associated with increased risk of acute
cardiovascular events[19] and that residual inflammatory burden
at hospital discharge is linked to post-discharge mortality.[20,21]
Whether the PAC itself or co-interventions promote increased
inflammatory burden remains to be investigated.
Although use of the PAC has declined in the US, several
hundreds of thousands of patients still receive it annually.[5] This
ongoing use despite failure of the prior clinical trials to
demonstrate benefit perhaps reflects a high physician comfort
level with the information provided by the PAC. Preference for the
PAC could be bolstered by the fact that the negative trials did not
conclusively demonstrate harm and could not exclude the
Figure 5. Cost-effectiveness of the Pulmonary Artery Catheter. The mean estimate of incremental costs and effects suggest that the PAC is
both more expensive and less effective (panel A). The 95% confidence ellipse only marginally dips below the 50 k/QALY willingness-to-pay threshold
with the vast majority of trials agreeing with the mean estimate that the PAC is an inferior strategy. The corresponding cost-effectiveness
acceptability curve conveys the probability of the PAC to be cost-effective at various willingness-to-pay thresholds (Panel B, x-axis). Even if
willingness-to-pay was unlimited, there is only a 20.8% probability of the PAC to be cost effective (Panel B, dotted line). The PAC displays a better
cost-effectiveness profile in subjects treated with a conservative fluid strategy (panel C) than those receiving a liberal strategy. A similar trend is seen
in subjects where the study protocol was instituted early after enrolment (panel D). Yet, for both subgroups, there was a high probability for the PAC
to be an ineffective strategy.
doi:10.1371/journal.pone.0022512.g005
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possibility of non-mortal benefits. However, in this era of
escalating healthcare costs it is hard to justify continued broad
use of an intervention with such a poor cost-effectiveness profile.
Rather, PAC use should probably be curtailed to select instances
where specific diagnostic information is required, such as in the
evaluation of suspected pulmonary hypertension.
As with prior studies on the effectiveness of the PAC, true
differences or lack thereof between treatment and control groups
might be veiled by unmeasured confounders. However, adding
cost of care information provides further evidence of the
robustness of a recommendation of highly discriminatory use of
the PAC. We performed four questionnaires in the first year.
Longitudinal trends observed in the recovery of utilities could not
have been detected with a sparser schedule. Yet our study also
suggests that a 3 month and 9 month follow-up would capture the
nadir and recovery of indices of quality of life while minimizing
burden on both subjects and researchers. Approximately a quarter
of questionnaires were filled with proxies, which may not be
particularly reliable for subjective information relating to quality of
life.[12,22] Our estimates are however quite robust to uncertainty
in quality of life of survivors and in fact to post-discharge costs
derived for the follow-up questionnaire. The willingness-to-pay
thresholds we used have been proposed several years ago and may
be too low today.[16,23] However, the conclusions did not change
using more generous thresholds. We did not provide a formal
ICER for a PAC-based strategy because such a ratio is only
informative (and sensible) for effective strategies.[24] Follow-up
beyond one year would have been desirable to determine whether
the high resource use and mortality in the first year continued.
Our study was conducted from a societal perspective with a
reference case that includes a lifetime horizon. From a healthcare
provider’s perspective, added hospital costs of the index hospital-
ization with the PAC would likely not effect reimbursements, while
post-discharge costs may likely be cost-neutral, resulting also in an
unfavorable cost-effectiveness profile.
The use of the PAC in patients with ALI appears to increase
costs of care, produces no short or long-term benefit, and is
associated with trends towards worse outcome in some long-term
measures. This unfavorable cost-effectiveness profile does not
justify routine use of the PAC in patients with ALI and broadens
the conclusions of a large short-term efficacy trial.
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